Core Viewpoint - TELA Bio, Inc. reported strong financial results for Q4 and full year 2025, with significant revenue growth and improved gross margins, while maintaining flat operating expenses, indicating operational leverage and confidence in future growth [3][4][8]. Financial Performance - Q4 2025 revenue reached $20.9 million, an 18% increase from Q4 2024, driven by new customer additions, the U.S. launch of a larger OviTex PRS product, and increased international sales [4][10]. - Full year 2025 revenue totaled $80.3 million, a 16% increase compared to 2024, attributed to similar factors as the quarterly growth [8][10]. - Gross profit for Q4 2025 was $13.8 million, representing 65.9% of revenue, up from 63.6% in Q4 2024, primarily due to lower inventory-related expenses [5][10]. - For the full year 2025, gross profit was $54.3 million, or 67.7% of revenue, compared to 67.1% in 2024, reflecting improved inventory cost management [9][11]. Operating Expenses and Losses - Operating expenses in Q4 2025 were $20.4 million, slightly higher than $19.6 million in Q4 2024, driven by increased compensation costs and higher study and professional fees [6][10]. - The loss from operations for Q4 2025 was $6.6 million, an improvement from a loss of $8.4 million in Q4 2024 [7][10]. - For the full year 2025, the loss from operations was $33.8 million, a slight improvement from $34.1 million in 2024 [11][12]. Cash Position and Debt - As of December 31, 2025, TELA Bio had cash and cash equivalents of $50.8 million, down from $52.7 million in 2024 [12][19]. - The company closed a credit facility for up to $70 million, which includes an initial loan of $60 million, aimed at supporting future growth [10]. Future Outlook - TELA Bio anticipates at least 8% revenue growth in 2026, with first quarter revenue projected at approximately $18.5 million [16]. - The company has strengthened its sales force to 89 revenue-generating representatives, enhancing its market penetration capabilities [3][10].

Core Insights - TELA Bio, Inc. has appointed William Plovanic, CFA, to its Board of Directors, enhancing its leadership with expertise in capital markets and medical technology operations [1][3]. Group 1: Appointment Details - William Plovanic brings over 25 years of experience in capital markets, corporate strategy, and medical device operations [4][5]. - He currently serves as Managing Director of Healthcare Equity Research at Canaccord Genuity and has held C-level roles at Obalon Therapeutics from 2016 to 2021 [2][5]. Group 2: Company Strategy and Vision - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's anatomy [7]. - The company aims to provide advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [7]. Group 3: Leadership Perspective - The CEO of TELA Bio, Antony Koblish, expressed confidence that Plovanic's experience will strengthen the company's strategy and drive long-term shareholder value [3]. - Plovanic stated his honor in joining TELA Bio at a pivotal stage, highlighting the company's leadership in redefining soft-tissue reconstruction [3].

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy [2] - The company aims to provide advanced and economically effective solutions for surgeons, leveraging the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [2] Upcoming Events - TELA Bio will participate in the Canaccord Genuity 45 Annual Growth Conference, with management scheduled to present on August 13, 2025, at 10:00 am ET [1] - Interested parties can access the live and archived webcast of the presentation at ir.telabio.com [1]

Core Viewpoint - TELA Bio, Inc. has appointed Jeffrey Blizard as President to enhance its leadership team and drive the next phase of growth in the medical technology sector, particularly in soft-tissue reconstruction solutions [1][2]. Leadership Changes - Jeffrey Blizard, previously on TELA Bio's Board of Directors, brings extensive industry experience and a successful track record from his role as Global Head of Surgical Sales at Abiomed, contributing to significant growth in that division [1][2]. - The CEO of TELA Bio, Antony Koblish, emphasized that Blizard's leadership will enhance the company's competitive edge and commercial performance in a dynamic market [2]. Company Overview - TELA Bio, Inc. is focused on innovative technologies for soft-tissue reconstruction, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [3]. - The company is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing reliance on permanent synthetic materials [3].

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [2] - The company aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy [2] - TELA Bio provides advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [2] Upcoming Events - TELA Bio will participate in the 2025 Jefferies Global Healthcare Conference [1] - The management is scheduled to present at 11:05 am ET on June 5, 2025 [1] - Interested parties can access the live and archived webcast at ir.telabio.com [1]